Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00231894
Status:
COMPLETED
Last Update Posted:
2017-12-11
First Post:
2005-10-03
Brief Title:
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
Sponsor:
Nathan Kline Institute for Psychiatric Research
Organization:
Nathan Kline Institute for Psychiatric Research
Study Overview
Official Title:
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function
Status:
COMPLETED
Status Verified Date:
2017-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study with an approved drug for treating type 2 diabetes for its effects on treating glucose and lipid abnormalities in patients being treated with first or second-generation antipsychotics and comparison of effects of this drug with another treatment lifestyle modification Patients who meet inclusion criteria will be treated with pioglitazone for 12 weeks They will be evaluated for fasting glucose and lipids glucose-tolerance tests and neurocognitive battery and tests of verbal memory at baseline and during treatment with pioglitazone
Detailed Description:
The aim of this study is to investigate the effects of pioglitazone added to weight-lifestyle intervention vs placebo plus lifestyle intervention on reversing or reducing impaired or abnormal triglycerides HDL and glucose metabolism in schizophrenics treated with first or second-generation antipsychotics Another aim is to examine the effects of impaired glucose metabolism on verbal memory and other cognitive function in schizophrenic patients treated with these medications and the relationship to improvements in impaired glucose metabolism to impairments in cognitive function Clozapine and olanzapine and some other first or second-generation antipsychotics effective for treating schizophrenia and bipolar disorders have been reported to be associated with increased incidence of diabetic type metabolic abnormalities decreases in insulin sensitivity and abnormal glucose tolerance tests This can lead to the development of type 2 diabetes and also abnormal lipid metabolic levels which can lead to atherosclerotic changes and increased risk of cardiovascular disease and other diabetes related complications Drug treatments which could reduce or correct these diabetic metabolic changes would permit many patients to continue to receive the benefits of these antipsychotic medications with reduced drug-induced comorbidity Previous research using non-psychotic subjects has shown that diabetes and impaired glucose tolerance are associated with cognitive impairments especially in verbal memory and provides a rationale for testing whether corrections of impaired glucose metabolism are associated with cognitive improvements in schizophrenic patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 04T-584 | OTHER_GRANT | Stanley Foundation | None |